PIK3CD and glioblastoma: On the other hand increased PI3K-C2β protein levels significantly correlates with resistance to Erlotinib in GBM thus suggesting that targeting of PI3K-C2β in resistant GBM may represent a new therapeutic approach (Low et al., 2008).